Updated on 17.12.2025 @ 10:49 AM
Nephrocare Health Services Limited is set to launch its mainboard Initial Public Offering (IPO) on December 10, 2025. It is India's largest dialysis service provider.
If you actively track new issues, you can also check our Upcoming and Live IPOs Calendar for all current listings and schedules
The company aims to raise up to ₹871.05 crores through a mix of a fresh issue and a significant Offer for Sale (OFS).
The price band has been fixed at ₹438 to ₹460 per share, with a minimum lot size of 32 shares.
Nephrocare has shown a strong financial turnaround, moving from losses to solid profitability, but investors should be mindful of the large OFS component and the specialized nature of its business. For those building long-term wealth alongside IPO investing, you may also explore our Mutual Fund Learning Hub and use our SIP Calculator to plan your investments better.
In this article, you will find Nephrocare Health Services IPO GMP today, subscription status, allotment date, price band, and a detailed, unbiased review to help you make an informed decision.
Briefs of Nephrocare Health Services IPO Details
- Price Band: ₹438 – ₹460 per share
- IPO Open / Close Dates: December 10, 2025 – December 12, 2025
- Lot Size: 32 Shares
- Issue Size: ₹871.05 Crores (Fresh Issue of ₹353.40 Cr + OFS of ₹517.64 Cr)
- Fresh Issue / OFS: Both
- Registrar: Kfin Technologies Ltd.
- Listing Exchange: BSE & NSE
What is The Nephrocare Health Services IPO GMP Today?
Check the GMP of this and all other important IPOs at a single place. Grey market premium hub page. (GMP is unoffical data, it is not regulated by any government agencies).
Listing Updates:
| Type | Issue Price | Open | Gain/loss |
| Lisiting | 460 | 490 | 6.5 |
Nephrocare Health Services IPO Dates & Allotment Schedule
- IPO Open & Close Date: December 10, 2025 – December 12, 2025
- Basis of Allotment Date: December 15, 2025
- Refund Initiation Date: December 16, 2025
- Credit of Shares: December 16, 2025
- Listing Date: December 17, 2025
Objectives of Nephrocare Health Services IPO
The company intends to utilise the net proceeds from the fresh issue for its strategic expansion and debt reduction:
- Capital Expenditure for New Clinics (₹129.11 Crores): A significant portion is allocated to open new dialysis clinics across India, expanding its network.
- Repayment of Borrowings (₹136.00 Crores): To prepay or repay certain outstanding loans, which will reduce finance costs and strengthen the balance sheet.
- General Corporate Purposes: The balance amount will be used for other strategic requirements.
- Note: The majority of the IPO proceeds (₹517.64 crores) is an Offer for Sale, meaning this money will go to selling shareholders and promoters, not the company.
How is The Financial Performance of Nephrocare Health Services?
The following table summarizes the company's financial performance based on restated consolidated data.
(Amounts in ₹ Crores)
Particulars | Period Ended 30 Sep 2025 (6M) | Year Ended 31 Mar 2025 | Year Ended 31 Mar 2024 | Year Ended 31 Mar 2023 |
Total Income | 483.97 | 769.92 | 574.72 | 443.26 |
Profit After Tax (PAT) | 14.23 | 67.10 | 35.13 | (11.79) |
EBITDA | 110.31 | 166.64 | 99.66 | 48.60 |
Net Worth | 716.06 | 594.21 | 423.55 | 384.73 |
Total Borrowing | 207.04 | 225.80 | 243.37 | 196.21 |
Assets | 1,193.68 | 996.46 | 806.02 | 666.23 |
Source: RHP
Key Financial Observations:
Profit After Tax (PAT):
Nephrocare has achieved a remarkable turnaround, moving from a loss of ₹11.79 Crores in FY23 to a solid profit of ₹67.10 Crores in FY25. This shift to profitability underscores the scalability of its dialysis clinic model.
Total Income:
Revenue has grown consistently at a CAGR of over 31% between FY23 and FY25. The H1-FY26 revenue of ₹483.97 Crores suggests continued strong momentum, driven by domestic expansion and increasing international revenue.
EBITDA:
Operational profit has more than tripled in two years, with EBITDA margins expanding from 11% to over 22%. This indicates significant improvements in operational efficiency and cost management.
Total Borrowings:
While absolute debt stood at ₹207.04 Crores as of September 2025, the IPO proceeds allocated for repayment will help significantly lower the debt burden and interest costs.
Assets:
Total assets have nearly doubled since FY23 to ₹1,193.68 Crores, reflecting heavy investment in expanding the clinic network and infrastructure.
P/E Ratio & Peer Comparison
Based on its Fiscal Year 2025 earnings per share (EPS) of ₹8.28, the IPO is priced at a Price-to-Earnings (P/E) multiple of approximately 55.6x at the upper end of the price band (₹460).
P/E Ratio = ₹460 (Price) / ₹8.28(Earnings Per Share)
P/E Ratio ≈ 55.6x
This valuation appears reasonable when compared to its listed industry peers in the healthcare services sector.
Company Name | P/E Ratio | Revenue (FY25, ₹ Cr) | RoE (%) (FY25) | EBITDA Margin (%) (FY25) |
Nephrocare Health (at IPO price) | ~55.6 | 769.92 | 13.45% | 22.05% |
Narayana Health | 45.21 | 5,482.98 | 24.25% | 23.13% |
Rainbow Children's Medicare | 56.84 | 1,515.87 | 23.83% | 32.32% |
Jupiter Life Line Hospitals | 51.10 | 1,261.55 | 15.33% | 23.51% |
Analysis for Investors:
Nephrocare is priced at a P/E of ~55.6x, which is in line with peers like Rainbow Children's Medicare (56.8x) and Jupiter Life Line Hospitals (51.1x). While Narayana Health trades at a lower valuation, Nephrocare's specialised niche in dialysis and its faster growth rate (from a smaller base) could justify the valuation. The IPO pricing seems fair, leaving room for growth if the company continues its expansion trajectory.
Industry Outlook
- The demand for dialysis services in India is growing rapidly due to the increasing prevalence of chronic kidney diseases (CKD) and diabetes.
- The market is largely unorganized, presenting a massive opportunity for organized players like Nephrocare to consolidate market share.
- As the largest player with a pan-India presence and growing international footprint, Nephrocare is well-positioned to benefit from the structural tailwinds in the healthcare sector.
What Are The Strengths and Risks of Nephrocare Health Services IPO?
Strengths:
- Market Leadership: India's largest dialysis service provider with a dominant market share.
- Financial Turnaround: Successfully transitioned from losses to robust profitability with expanding margins.
- Operational Scale: A vast network of over 500 clinics provides economies of scale and brand visibility.
- Global Expansion: Growing revenue contribution from international markets like the Philippines and Uzbekistan.
Risks:
- Large Offer for Sale (OFS): The majority of the IPO proceeds go to selling shareholders, not the company.
- Regulatory Risks: The healthcare sector is subject to stringent regulations and price controls.
- Dependence on Hospital Partnerships: A significant portion of revenue comes from captive clinics within hospitals, which rely on contract renewals.
- Capital Intensive: Expansion requires continuous capital expenditure for setting up new clinics and maintaining equipment.
What Are The Expert Recommendations – Should You Apply?
Read the RHP carefully before investing, this is not an investment advice.
The Nephrocare Health Services IPO offers a unique opportunity to invest in a specialized healthcare leader with a strong growth trajectory.
- For Value Investors: The valuation is fair relative to peers, though not cheap. The financial turnaround makes it an interesting pick.
- For Growth Investors: The company's leadership position in a high-growth niche and its international expansion plans offer significant upside.
- Our View: Despite the large OFS, the company's strong fundamentals, leadership status, and improving financial health make it a solid investment. We recommend "Subscribe for Long-Term" for investors who believe in the organized healthcare growth story.
Key Takeaways
- IPO Price Band: ₹438 to ₹460 per share
- Lot Size: 32 Shares (Minimum Investment: ₹14,720)
- GMP Today: ₹0 (Not trading)
- Allotment & Listing Dates: Tentative listing on December 17, 2025.
- Recommendations of experts: A "Subscribe for Long-Term" recommendation. A market leader in dialysis services with strong financials, offered at a fair valuation.
FAQs on Nephrocare Health Services IPO
What is Nephrocare Health Services IPO price band?
The price band for the IPO is set at ₹438 to ₹460 per equity share.
What is Nephrocare Health Services IPO allotment date?
The allotment of shares is tentatively expected to be finalized on Monday, December 15, 2025.
How to check Nephrocare Health Services IPO allotment status?
You can check the allotment status on the website of the IPO registrar once the basis of allotment is finalized. You can check ipo allotment status of this and other others IPOs at our IPO allotment status hub page.
What is Nephrocare Health Services IPO listing date?
The company's shares are tentatively scheduled to be listed on the BSE and NSE on Wednesday, December 17, 2025.
Should I apply for Nephrocare Health Services IPO?
Yes, this is a recommended IPO for long-term investors. The company is a market leader with strong growth and profitability, and is offered at a valuation comparable to its peers.
IPO Disclaimer:
All IPO details shared are based on publicly available information and may change. This is not investment advice. Always do your own research and consult a SEBI-registered advisor before making any investment decisions.
